Education
About Us
Working with TipRanks
Follow Us
Zymeworks Inc (ZYME)
NASDAQ:ZYME
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.69Last Year’s EPS
-0.42Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 05, 2025
|% Change Since: -11.23%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Positive
The earnings call reflected significant achievements in regulatory approvals and strategic partnerships, indicating strong progress and an optimistic outlook for Zymeworks. Despite some financial setbacks such as increased net loss and a program discontinuation, the company maintains a solid financial position and continues to innovate across its pipeline.Company Guidance
During the Zymeworks Fourth Quarter and Year-end 2024 Results Conference Call, the company provided detailed guidance on its financial and strategic outlook. Zymeworks reported a net loss of $122.7 million for 2024, an increase from $118.7 million in 2023, mainly due to a $17.3 million non-cash impairment charge. Revenue for 2024 was $76.3 million, driven by milestone revenues from partnerships, including $25 million from Jazz Pharmaceuticals. The company achieved a $14 million research milestone from GSK. Operating expenses remained stable at $213.4 million, with a slight year-over-year increase of 0.3%. Zymeworks ended the year with $324.2 million in cash resources, providing a cash runway into the second half of 2027. The company also highlighted progress in its R&D pipeline, focusing on advancing its wholly-owned therapeutics in oncology and autoimmune diseases, and emphasized its strong global partnerships as key contributors to its strategic growth and innovation.Approval of Zanidatamab
Zymeworks reported the approval of zanidatamab, marking a significant milestone in their clinical development strategy.
Strong Partnerships and Milestone Achievements
Zymeworks earned over $45 million from partnerships in the past 12 months, including a $14 million research milestone from GSK and various milestone revenues from Jazz and BeiGene.
Progress in Autoimmune and Inflammatory Diseases
Expansion into autoimmune and inflammatory diseases, highlighting their R&D focus and potential for innovation.
Strong Financial Position
Zymeworks reported $324.2 million in cash resources as of December 31, 2024, providing an expected cash runway into the second half of 2027.
R&D Day Announcements
Nomination of ZW209, a next-generation T cell engager, and ZW1528 for autoimmune and inflammatory diseases, showcasing continued innovation.
---
ZYME Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ZYME Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 05, 2025 | $13.18 | $12.13 | -7.97% |
| Oct 31, 2024 | $13.70 | $13.28 | -3.07% |
| Aug 01, 2024 | $10.11 | $10.20 | +0.89% |
| May 02, 2024 | $9.00 | $9.20 | +2.22% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Zymeworks Inc (ZYME) report earnings?
Zymeworks Inc (ZYME) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is Zymeworks Inc (ZYME) earnings time?
Zymeworks Inc (ZYME) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ZYME EPS forecast?
ZYME EPS forecast for the fiscal quarter 2025 (Q1) is -0.69.
---